Sovaldi Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

sovaldi

gilead sciences ireland uc - sofosbuvir - hepatite c, crônica - antivirais para uso sistêmico - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 e 5. para o vírus da hepatite c (vhc) genótipo atividade específica, consulte as secções 4. 4 e 5. sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 e 5. para o vírus da hepatite c (vhc) genótipo atividade específica, consulte as secções 4. 4 e 5.

Vosevi Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

vosevi

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatite c, crônica - antivirais para uso sistêmico - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (consulte as secções 4. 2, 4. 4 e 5.

Biktarvy Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

biktarvy

gilead sciences ireland uc - bictegravir, emtricitabina, tenofovir alafenamide, fumarato - infecções por hiv - antivirais para uso sistêmico - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (ver secção 5.

VIREAD Brazili - Kireno - ANVISA (Agência Nacional de Vigilância Sanitária)

viread

gilead sciences farmaceutica do brasil ltda - fumarato de tenofovir desoproxila - antiretroviral

Vemlidy Brazili - Kireno - ANVISA (Agência Nacional de Vigilância Sanitária)

vemlidy

gilead sciences farmaceutica do brasil ltda - hemifumarato de tenofovir alafenamida - antiinfecciosos para uso sistÊmico; antivirais para uso sistÊmico; antivirais de aÇÃo direta; nucelosÍdeos e nucelotÍdeos inibidores da transcriptase reversa

Veklury Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

veklury

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Hepcludex Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

hepcludex

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirais para uso sistêmico - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

VEKLURY® Brazili - Kireno - ANVISA (Agência Nacional de Vigilância Sanitária)

veklury®

gilead sciences farmaceutica do brasil ltda - rendesivir - antiviroticos

Trodelvy Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

trodelvy

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - agentes antineoplásicos - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Sunlenca Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

sunlenca

gilead sciences ireland unlimited company - lenacapavir sodium - infecções por hiv - antivirais para uso sistêmico - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 e 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 e 5.